MEN1 and leukemia: In a Phase I/II clinical trial for the MENIN inhibitor Revumenib (SNDX-5613; NCT04065399), 33% of patients with relapsed or refractory KMT2A-r leukemia achieved complete remission while receiving Revumenib as monotherapy.